Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals.
Study Goal
The researchers aimed to investigate how dietary n3 PUFAs from fish interact with adiponectin gene polymorphisms to influence serum adiponectin concentrations.
Results Summary
The study found that the -11391 A-allele was associated with higher baseline adiponectin levels, and individuals homozygous for the +45 T-allele aged >58 years showed a 22% increase in adiponectin after the highest n3 PUFA dose. The interaction between treatment, age, and genotype was significant, suggesting potential benefits for older individuals with specific genetic profiles.
Population
142 healthy men and 225 women aged 45-70 years.
Effective Dosage
0.45, 0.9, and 1.8 g/d of 20:5n3 and 22:6n3 (1.51:1 ratio).
Duration
12 months.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Marine n3 polyunsaturated fatty acids (PUFAs) | increase | the transcription factor peroxisome proliferator-activated receptor (PPARγ) | - | - | activate | #1 |
Marine n3 polyunsaturated fatty acids (PUFAs) | increase | adiponectin | - | - | modulates the expression of | #2 |
The -11391 A-allele | increase | serum adiponectin concentration | participants at baseline (n = 290) | - | was associated with a higher | #3 |
treatment with doses of 0.45, 0.9, and 1.8 g/d 20:5n3 and 22:6n3 (1.51:1) | increase | adiponectin | participants aged >58 y after the highest dose (n = 92) | - | interaction between treatment and age as a determinant of adiponectin was significant in | #4 |
treatment with doses of 0.45, 0.9, and 1.8 g/d 20:5n3 and 22:6n3 (1.51:1) | increase | serum adiponectin | participants after adjustment for BMI, gender, and ethnicity | - | interaction between +45 T/G and treatment and age was a nominally significant determinant of | #5 |
the highest dose of n3 PUFAs (1.8 g/d 20:5n3 and 22:6n3) | increase | serum adiponectin concentration | Individuals homozygous for the +45 T-allele aged >58 y | 22% | had a 22% increase in | #6 |
a diet high in n3 PUFAs | decrease | hypoadiponectinemia, type 2 diabetes, and obesity risk | older individuals, especially those of the +45 TT genotype | - | may be recommended for | #7 |
Marine n3 polyunsaturated fatty acids (PUFAs) activate the transcription factor peroxisome proliferator-activated receptor (PPARγ), which modulates the expression of adiponectin. We investigated the interaction of dietary n3 PUFAs with adiponectin gene (ADIPOQ) single nucleotide polymorphism (SNP) genotypes as a determinant of serum adiponectin concentration. The Modulation of Atherosclerosis Risk by Increasing Doses of n3 Fatty Acids study is a parallel design, double-blind, controlled trial. Serum adiponectin was measured in 142 healthy men and 225 women aged 45-70 y randomized to treatment with doses of 0.45, 0.9, and 1.8 g/d 20:5n3 and 22:6n3 (1.51:1), or placebo for 12 mo. The 310 participants who completed the study were genotyped for 5 SNPs at the ADIPOQ locus: -11391 G/A (rs17300539), -11377 C/G (rs266729), -10066 G/A (rs182052), +45 T/G (rs2241766), and +276 G/T (rs1501299). The -11391 A-allele was associated with a higher serum adiponectin concentration at baseline (n = 290; P < 0.001). The interaction between treatment and age as a determinant of adiponectin was significant in participants aged >58 y after the highest dose (n = 92; P = 0.020). The interaction between +45 T/G and treatment and age was a nominally significant determinant of serum adiponectin after adjustment for BMI, gender, and ethnicity (P = 0.029). Individuals homozygous for the +45 T-allele aged >58 y had a 22% increase in serum adiponectin concentration compared with baseline after the highest dose (P-treatment effect = 0.008). If substantiated in a larger sample, a diet high in n3 PUFAs may be recommended for older individuals, especially those of the +45 TT genotype who have reported increased risk of hypoadiponectinemia, type 2 diabetes, and obesity.